Mortality of COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation During the Three Epidemic Waves

Clinical presentation and mortality of patients treated with extracorporeal membrane oxygenation (ECMO) for COVID-19 acute respiratory distress syndrome (CARDS) were different during the French epidemic waves. The management of COVID-19 patients evolved through waves as much as knowledge on that new viral disease progressed. We aimed to compare the mortality rate through the first three waves of CARDS patients on ECMO and identify associated risk factors. Fifty-four consecutive ECMO for CARDS hospitalized at Amiens University Hospital during the three waves were included. Patients were divided into three groups according to their hospitalization date. Clinical characteristics and outcomes were compared between groups. Pre-ECMO risk factors predicting 90 day mortality were evaluated using multivariate Cox regression. Among 54 ECMO (median age of 61[48–65] years), 26% were hospitalized during the first wave (n = 14/54), 26% (n = 14/54) during the second wave, and 48% (n = 26/54) during the third wave. Time from first symptoms to ECMO was higher during the second wave than the first wave. (17 [12–23] days vs. 11 [9–15]; p < 0.05). Ninety day mortality was higher during the second wave (85% vs. 43%; p < 0.05) but less during the third wave (38% vs. 85%; P < 0.05). Respiratory ECMO survival prediction score and time from symptoms onset to ECMO (HR 1.12; 95% confidence interval [CI]: 1.05–1.20; p < 0.001) were independent factors of mortality. After adjustment, time from symptoms onset to ECMO was an independent factor of 90 day mortality. Changes in CARDS management from first to second wave-induced a later ECMO cannulation from symptoms onset with higher mortality during that wave. The duration of COVID-19 disease progression could be selection criteria for initiating ECMO.

[1]  Arthur S Slutsky,et al.  Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic , 2021, Critical Care.

[2]  M. Vallverdú,et al.  Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study , 2021, The Lancet Regional Health - Europe.

[3]  Ryan P. Barbaro,et al.  Correction to: Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis , 2021, Critical Care.

[4]  A. Vincentelli,et al.  Extracorporeal Membrane Oxygenation for COVID 2019-Acute Respiratory Distress Syndrome: Comparison between First and Second Waves (Stage 2) , 2021, Journal of clinical medicine.

[5]  P. Leprince,et al.  Evolving outcomes of extracorporeal membrane oxygenation support for severe COVID-19 ARDS in Sorbonne hospitals, Paris , 2021, Critical Care.

[6]  M. Baram,et al.  OUTCOMES OF EXTRACORPOREAL MEMBRANE OXYGENATION IN ARDS DUE TO COVID-19: COMPARISON OF THE FIRST AND THE SECOND WAVE , 2021, Chest.

[7]  M. Katz,et al.  Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery. , 2021, JAMA internal medicine.

[8]  S. Eksborg,et al.  Extracorporeal membrane oxygenation for COVID-19 during first and second waves , 2021, The Lancet Respiratory Medicine.

[9]  P. Pelosi,et al.  Noninvasive respiratory support and patient self-inflicted lung injury in COVID-19: a narrative review , 2021, British Journal of Anaesthesia.

[10]  C. Thilo,et al.  Comparison of the First and Second Waves of Hospitalized Patients With SARS-CoV-2. , 2021, Deutsches Arzteblatt international.

[11]  A. Jha,et al.  Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom , 2021, Acute and critical care.

[12]  P. Leprince,et al.  ECMO for COVID-19 patients in Europe and Israel , 2021, Intensive Care Medicine.

[13]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[14]  J. Fraser,et al.  Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality? , 2020, Intensive Care Medicine.

[15]  Y. Mahjoub,et al.  Extracorporeal membrane oxygenation for respiratory failure in COVID-19 patients: outcome and time-course of clinical and biological parameters , 2020, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[16]  Y. Mahjoub,et al.  COVID-19 Outbreak in France: Setup and Activities of a Mobile Extracorporeal Membrane Oxygenation Team During the First 3 Weeks , 2020, Journal of Cardiothoracic and Vascular Anesthesia.

[17]  Y. Mahjoub,et al.  ECMO for COVID-19 associated severe ARDS and risk of thrombosis , 2020, British Journal of Anaesthesia.

[18]  J. Bazin,et al.  French legal approach to clinical research. , 2018, Anaesthesia, critical care & pain medicine.

[19]  D. Brodie,et al.  Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome , 2018, The New England journal of medicine.

[20]  D. Brodie,et al.  Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. , 2014, American journal of respiratory and critical care medicine.

[21]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[22]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.